JP2014533277A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014533277A5 JP2014533277A5 JP2014541310A JP2014541310A JP2014533277A5 JP 2014533277 A5 JP2014533277 A5 JP 2014533277A5 JP 2014541310 A JP2014541310 A JP 2014541310A JP 2014541310 A JP2014541310 A JP 2014541310A JP 2014533277 A5 JP2014533277 A5 JP 2014533277A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- administered
- inhibitor
- subject
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 28
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims 22
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 22
- 239000003112 inhibitor Substances 0.000 claims 22
- 229940124302 mTOR inhibitor Drugs 0.000 claims 22
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 22
- 239000003814 drug Substances 0.000 claims 18
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 239000000825 pharmaceutical preparation Substances 0.000 claims 13
- 229940127557 pharmaceutical product Drugs 0.000 claims 13
- 201000011510 cancer Diseases 0.000 claims 9
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 9
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 9
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 7
- 229960005167 everolimus Drugs 0.000 claims 7
- 238000009472 formulation Methods 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- -1 SAR543 Chemical compound 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 230000000762 glandular Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- GYLDXIAOMVERTK-UHFFFAOYSA-N 5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine Chemical compound C12=C(N)N=CN=C2N(C(C)C)N=C1C1=CC=C(OC(N)=N2)C2=C1 GYLDXIAOMVERTK-UHFFFAOYSA-N 0.000 claims 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- 239000012635 anticancer drug combination Substances 0.000 claims 1
- ZDQSOHOQTUFQEM-PKUCKEGBSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C\C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-PKUCKEGBSA-N 0.000 claims 1
- ZDQSOHOQTUFQEM-XCXYXIJFSA-N ascomycin Natural products CC[C@H]1C=C(C)C[C@@H](C)C[C@@H](OC)[C@H]2O[C@@](O)([C@@H](C)C[C@H]2OC)C(=O)C(=O)N3CCCC[C@@H]3C(=O)O[C@H]([C@H](C)[C@@H](O)CC1=O)C(=C[C@@H]4CC[C@@H](O)[C@H](C4)OC)C ZDQSOHOQTUFQEM-XCXYXIJFSA-N 0.000 claims 1
- JROFGZPOBKIAEW-UHFFFAOYSA-N chembl2132692 Chemical compound N1C=2C(OC)=CC=CC=2C=C1C(=C1C(N)=NC=NN11)N=C1C1CCC(C(O)=O)CC1 JROFGZPOBKIAEW-UHFFFAOYSA-N 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 1
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 229950009216 sapanisertib Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical group C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 238000011301 standard therapy Methods 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- 208000008732 thymoma Diseases 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
- 229950009819 zotarolimus Drugs 0.000 claims 1
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161558732P | 2011-11-11 | 2011-11-11 | |
| US61/558,732 | 2011-11-11 | ||
| PCT/US2012/064376 WO2013071056A2 (en) | 2011-11-11 | 2012-11-09 | Combination drug therapy for the treatment of solid tumors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014533277A JP2014533277A (ja) | 2014-12-11 |
| JP2014533277A5 true JP2014533277A5 (cg-RX-API-DMAC7.html) | 2015-12-24 |
| JP6268097B2 JP6268097B2 (ja) | 2018-01-24 |
Family
ID=48290768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541310A Active JP6268097B2 (ja) | 2011-11-11 | 2012-11-09 | 固形腫瘍治療のための併用薬物療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9700619B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2776042B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6268097B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012335541B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2852127C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2723827T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013071056A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1203378A1 (en) * | 2011-11-23 | 2015-10-30 | Intellikine, Llc | Enhanced treatment regimens using mtor inhibitors |
| KR20160079822A (ko) * | 2013-11-27 | 2016-07-06 | 온코에틱스 게엠베하 | 티에노트리아졸로디아제핀 화합물을 함유하는 제약 제제를 사용하여 비소세포성 폐암을 치료하는 방법 |
| CA2951211A1 (en) | 2014-06-13 | 2015-12-17 | Oncoethix Gmbh | Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds |
| EP3215175A4 (en) | 2014-11-06 | 2018-06-27 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| WO2017015622A2 (en) * | 2015-07-22 | 2017-01-26 | Scholar Rock, Inc | Gdf11 binding proteins and uses thereof |
| ES3030258T3 (en) | 2015-09-15 | 2025-06-27 | Scholar Rock Inc | Anti-pro/latent-myostatin antibodies and uses thereof |
| JP2019504064A (ja) | 2016-01-08 | 2019-02-14 | スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． | 抗プロ／潜在型ミオスタチン抗体およびその使用方法 |
| KR102271635B1 (ko) | 2016-06-13 | 2021-07-06 | 스칼러 락, 인크. | 미오스타틴 억제제의 용도 및 조합 요법 |
| HUE061656T2 (hu) | 2017-01-06 | 2023-07-28 | Scholar Rock Inc | Metabolikus betegségek kezelése a miosztatin aktiválás gátlásával |
| WO2019046600A1 (en) * | 2017-08-30 | 2019-03-07 | Amgen Inc. | INSULIN-RELATED GROWTH FACTOR 1 RECEPTOR BINDING PROTEINS (IGF-1R) AND METHODS OF USE |
| AU2023413166A1 (en) | 2022-12-22 | 2025-07-03 | Scholar Rock, Inc. | Selective and potent inhibitory antibodies of myostatin activation |
| US20250062020A1 (en) * | 2023-08-14 | 2025-02-20 | Tempus Ai, Inc. | Systems and methods of radiomics based cancer stratification |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2714383B1 (fr) | 1993-12-29 | 1996-02-09 | Centre Nat Rech Scient | Contrôle de l'expression de gènes. |
| EP1034188B1 (en) | 1997-11-27 | 2006-06-07 | Commonwealth Scientific And Industrial Research Organisation | Method of designing agonists and antagonists to igf receptor (1-462) |
| AU4079999A (en) | 1998-05-15 | 1999-12-06 | Imclone Systems Incorporated | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases |
| US20030236190A1 (en) | 1998-09-02 | 2003-12-25 | Renuka Pillutla | Isulin and IGF-1 receptor agonists and antagonists |
| US7173005B2 (en) | 1998-09-02 | 2007-02-06 | Antyra Inc. | Insulin and IGF-1 receptor agonists and antagonists |
| US6875741B2 (en) | 1998-09-02 | 2005-04-05 | Renuka Pillutla | Insulin and IGF-1 receptor agonists and antagonists |
| EP1006184A1 (en) | 1998-12-03 | 2000-06-07 | F. Hoffmann-La Roche Ag | IGF-1 receptor interacting proteins (IIPs) genes coding therefor and uses thereof |
| US6608108B2 (en) | 1999-10-15 | 2003-08-19 | Johns Hopkins University | Method for treatment of tumors using nordihydroguaiaretic acid derivatives |
| ES2344592T3 (es) | 2001-01-05 | 2010-09-01 | Pfizer Inc. | Anticuerpos frente al receptor del factor de crecimiento similar a la insulina i. |
| CA2439735A1 (en) | 2001-03-14 | 2002-09-19 | Genentech, Inc. | Igf antagonist peptides |
| SE0104140D0 (sv) | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
| ES2283759T3 (es) | 2002-01-18 | 2007-11-01 | Pierre Fabre Medicament | Anticuerpos anti-igf-ir y sus aplicaciones. |
| US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| EP1432724A4 (en) | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | INTERFERENCE MEDIATION INHIBITION OF GENE RNA FROM MAP KINASE |
| NZ571508A (en) | 2002-05-24 | 2010-05-28 | Schering Corp | Neutralizing human anti-IGFR antibody |
| US8034904B2 (en) | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| US7803781B2 (en) | 2003-02-28 | 2010-09-28 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
| EP1603948A1 (en) | 2003-03-14 | 2005-12-14 | Pharmacia Corporation | Antibodies to igf-i receptor for the treatment of cancers |
| ES2383014T3 (es) | 2003-04-02 | 2012-06-15 | F. Hoffmann-La Roche Ag | Anticuerpos contra el factor I de crecimiento similar a insulina y usos de los mismos |
| US7638605B2 (en) | 2003-05-01 | 2009-12-29 | ImClone, LLC | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| AR046071A1 (es) | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
| SG132683A1 (en) | 2003-10-15 | 2007-06-28 | Osi Pharm Inc | Imidazopyrazine tyrosine kinase inhibitors |
| AR046639A1 (es) | 2003-11-21 | 2005-12-14 | Schering Corp | Combinaciones terapeuticas de anticuerpo anti- igfr1 |
| WO2005058967A2 (en) | 2003-12-16 | 2005-06-30 | Pierre Fabre Medicament | Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof |
| WO2005082415A2 (en) | 2004-02-25 | 2005-09-09 | Dana Farber Cancer Institute, Inc. | Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth |
| EP1732898B1 (en) | 2004-03-12 | 2008-01-23 | Analytecon S.A. | Tetrahydroisoquinoline- and tetrahydrobenzazepine derivatives as igf-1r inhibitors |
| MY143225A (en) | 2004-04-02 | 2011-03-31 | Osi Pharm Inc | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| EP1759020A4 (en) | 2004-06-21 | 2008-04-16 | Exelixis Inc | ACACS AS MODIFICATORS OF THE IGF PATH AND METHOD OF USE |
| MY139689A (en) | 2004-07-20 | 2009-10-30 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
| FR2873699B1 (fr) | 2004-07-29 | 2009-08-21 | Pierre Fabre Medicament Sa | Nouveaux anticorps anti igf ir rt leurs utilisations |
| AR050365A1 (es) | 2004-08-02 | 2006-10-18 | Osi Pharm Inc | Compuestos inhibidores de multi- quinasa pirrolopirimidina aril- amino sustituidos. |
| GB0426154D0 (en) | 2004-11-29 | 2004-12-29 | European Molecular Biology Lab Embl | IGF-1 novel peptides |
| MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| EP1841760B1 (en) | 2004-12-30 | 2011-08-10 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
| WO2006097800A2 (en) | 2005-02-10 | 2006-09-21 | UNIVERSITÄT KARLSRUHE (TH) FORSCHUNGSUNIVERSITÄT-GEGRüNDET 1825 | Method and device for determining material properties |
| JP2008542685A (ja) | 2005-05-05 | 2008-11-27 | ヴァロリザーシヨン・アッシュエスジ，ソシエテ・アン・コマンディット | サイトカイン受容体修飾因子及びその使用 |
| RU2502523C2 (ru) | 2005-06-17 | 2013-12-27 | Имклоун Элэлси | АНТИТЕЛА ПРОТИВ PDGFRα ДЛЯ ЛЕЧЕНИЯ ВТОРИЧНОЙ ОПУХОЛИ КОСТИ |
| WO2007000328A1 (en) | 2005-06-27 | 2007-01-04 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof |
| FR2888850B1 (fr) | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
| AU2006288846B2 (en) | 2005-09-09 | 2011-08-18 | Analytecon Sa | Isoquinolines as IGF-1R inhibitors |
| JP2009507820A (ja) | 2005-09-09 | 2009-02-26 | アナリットコン エス アー | Ｉｇｆ−１ｒ阻害剤としてのイソキノリン誘導体 |
| WO2007031745A1 (en) | 2005-09-16 | 2007-03-22 | Astrazeneca Ab | Pyrimidine derivatives for the inhibition of igf-ir tyrosine kinase activity |
| WO2007095113A2 (en) | 2006-02-10 | 2007-08-23 | Massachusetts Institute Of Technology | Cpg15 and cpg15-2 compounds and inhibitors as insulin receptor and insulin-like growth factor receptor agonists and antagonists |
| WO2007099166A1 (en) | 2006-03-03 | 2007-09-07 | Nerviano Medical Sciences S.R.L. | Pyrazolo-pyridine derivatives active as kinase inhibitors |
| ES2442491T3 (es) | 2006-03-03 | 2014-02-11 | Nerviano Medical Sciences S.R.L. | Biciclopirazoles activos como inhibidores de cinasa |
| SG170799A1 (en) | 2006-03-28 | 2011-05-30 | Biogen Idec Inc | Anti-igf-ir antibodies and uses thereof |
| CA2679548C (en) | 2007-03-02 | 2015-01-27 | Amgen Inc. | Methods and compositions for treating tumor diseases |
| US20090274698A1 (en) * | 2007-07-06 | 2009-11-05 | Shripad Bhagwat | Combination anti-cancer therapy |
| US20090263397A1 (en) * | 2007-07-06 | 2009-10-22 | Buck Elizabeth A | Combination anti-cancer therapy |
| AU2010236825A1 (en) * | 2009-04-16 | 2011-09-15 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
| US20100316639A1 (en) * | 2009-06-16 | 2010-12-16 | Genentech, Inc. | Biomarkers for igf-1r inhibitor therapy |
-
2012
- 2012-11-09 EP EP12848554.7A patent/EP2776042B1/en active Active
- 2012-11-09 CA CA2852127A patent/CA2852127C/en active Active
- 2012-11-09 WO PCT/US2012/064376 patent/WO2013071056A2/en not_active Ceased
- 2012-11-09 ES ES12848554T patent/ES2723827T3/es active Active
- 2012-11-09 JP JP2014541310A patent/JP6268097B2/ja active Active
- 2012-11-09 AU AU2012335541A patent/AU2012335541B2/en active Active
- 2012-11-09 US US14/357,039 patent/US9700619B2/en active Active
-
2017
- 2017-05-04 US US15/586,727 patent/US9931402B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014533277A5 (cg-RX-API-DMAC7.html) | ||
| JP5579715B2 (ja) | ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ | |
| Nobili et al. | Overcoming tumor multidrug resistance using drugs able to evade P‐glycoprotein or to exploit its expression | |
| ES2617689T3 (es) | Combinación terapéutica que comprende un inhibidor de PLK1 y un agente antineoplásico | |
| KR101848131B1 (ko) | 저용량 이리노테칸염산염 수화물을 함유하는 항종양제 | |
| CN111132696B (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| JP2019517549A5 (cg-RX-API-DMAC7.html) | ||
| KR20170098813A (ko) | 대장암 치료에 사용하기 위한 아필리모드 | |
| AU2011240001B2 (en) | Combination of organic compounds | |
| CN105283178A (zh) | 用于治疗癌症的包含mps-1激酶抑制剂和有丝分裂抑制剂的组合 | |
| Ahmad et al. | Review of the use of topotecan in ovarian carcinoma | |
| JP2021505669A5 (cg-RX-API-DMAC7.html) | ||
| Von Hoff et al. | 595 POSTER First Phase I trial of NKTR-102 (PEG-irinotecan) reveals early evidence of broad anti-tumor activity in three schedules | |
| EP1847274A1 (en) | Association of phenylbutyrate, ATRA and cytidine and its use in anti-tumour therapy | |
| KR101847252B1 (ko) | 이리노테칸염산염 수화물을 함유하는 항종양제 | |
| JP7468829B2 (ja) | 癌を処置するための、癌治療剤と組み合わせたＩＲＥ１α阻害剤 | |
| JP2015510945A5 (cg-RX-API-DMAC7.html) | ||
| Hu et al. | Current status of CPT and its analogues in the treatment of malignancies | |
| CN102648909B (zh) | 用在癌症治疗的敏化剂、试剂盒及用途 | |
| ES2896051T3 (es) | Fármaco antitumoral que contiene un complejo de platino antitumoral y un potenciador del efecto antitumoral | |
| Jeong et al. | Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial | |
| WO2023152337A1 (en) | An igf1r inhibitor and an akt inhibitor for use in the treatment of cancer | |
| JP2013510866A (ja) | 組み合わせたチボザニブおよびテムシロリムス | |
| CN102648911B (zh) | 用在靶向治疗的敏化剂、医药组合物、试剂盒及用途 |